Oncopeptides AB (publ) (STO: ONCO)

Market Cap	475.56M
Revenue (ttm)	21.37M
Net Income (ttm)	-262.70M
Shares Out	215.19M
EPS (ttm)	-1.22
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	268,824
Open	2.175
Previous Close	2.175
Day's Range	2.170 - 2.235
52-Week Range	1.998 - 10.200
Beta	-0.35
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 7, 2024

About Oncopeptides AB

Oncopeptides AB (publ), a biotech company, engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases in the United States, Europe, and internationally. Its lead product candidate is Pepaxti (melflufen), a drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. The company also engages in the research for small popypeptide based killer engages for the treatment of RRMM and hematological or solid tumors; and other peptide-drug conjugates for ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 57
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: ONCO

Financial Performance

In 2023, ISOFOL's revenue was 721,000, a decrease of -94.37% compared to the previous year's 12.80 million. Losses were -37.07 million, -76.80% less than in 2022.